{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:26:58Z","timestamp":1779114418776,"version":"3.51.4"},"reference-count":134,"publisher":"Tech Science Press","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":151,"URL":"https:\/\/doi.org\/10.32604\/TSP-CROSSMARKPOLICY"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.062207","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:55:50Z","timestamp":1746262550000},"page":"1271-1282","update-policy":"https:\/\/doi.org\/10.32604\/tsp-crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular insights into immune evasion in head and neck squamous cell carcinomas: Toward a promising treatment strategy"],"prefix":"10.32604","volume":"33","author":[{"given":"HYEON JI","family":"KIM","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BO KYUNG","family":"JOO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIN-SEOK","family":"BYUN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DO-YEON","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e007823","DOI":"10.1136\/jitc-2023-007823","article-title":"Association of a gene-expression subtype to outcome and treatment response in patients with recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab","volume":"12","author":"Serafini","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"100877","DOI":"10.1016\/j.esmoop.2023.100877","article-title":"Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study","volume":"8","author":"Sherman","year":"2023","journal-title":"ESMO Open"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/biology12020218","article-title":"Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors","volume":"12","author":"Dutta","year":"2023","journal-title":"Biology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s40001-022-00835-4","article-title":"Tumor microenvironment and immunotherapy of oral cancer","volume":"27","author":"Liu","year":"2022","journal-title":"Eur J Med Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e29386","DOI":"10.1002\/jmv.29386","article-title":"Deciphering head and neck cancer microenvironment: single-cell and spatial transcriptomics reveals human papillomavirus-associated differences","volume":"96","author":"Lee","year":"2024","journal-title":"J Med Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","article-title":"Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment","volume":"23","author":"Ruffin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e0274830","DOI":"10.1371\/journal.pone.0274830","article-title":"Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma","volume":"17","author":"Hur","year":"2022","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1002\/hed.26364","article-title":"Immune related proteins and tumor infiltrating CD8+ lymphocytes in hypopharyngeal cancer in relation to human papillomavirus (HPV) and clinical outcome","volume":"42","author":"Landin","year":"2020","journal-title":"Head Neck"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2019.04.032","article-title":"IL-6 induced M1 type macrophage polarization increases radiosensitivity in HPV positive head and neck cancer","volume":"456","author":"Chen","year":"2019","journal-title":"Cancer Lett"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00262-021-02874-y","article-title":"The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC","volume":"70","author":"Kouck\u00fd","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/ijc.29962","article-title":"CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma","volume":"138","author":"Wagner","year":"2016","journal-title":"Int J Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3892\/or.2020.7628","article-title":"M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF","volume":"44","author":"Fu","year":"2020","journal-title":"Oncol Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41597-023-02611-3","article-title":"Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer","volume":"10","author":"Wang","year":"2023","journal-title":"Sci Data"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.3390\/cancers15245814","volume":"15","author":"Mart\u00ednez-Barajas","year":"2023","journal-title":"Cancers"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3389\/fonc.2020.01701","article-title":"Immunological network in head and neck squamous cell carcinoma-a prognostic tool beyond HPV status","volume":"10","author":"Fialov\u00e1","year":"2020","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.7150\/ijbs.58077","article-title":"Therapeutic strategies of different HPV status in head and neck squamous cell carcinoma","volume":"17","author":"Sun","year":"2021","journal-title":"Int J Biol Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"104373","DOI":"10.1016\/j.ebiom.2022.104373","article-title":"Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification","volume":"86","author":"Zeng","year":"2022","journal-title":"EBioMedicine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/hed.27718","article-title":"Differential modulation of PI3K\/Akt\/mTOR activity by EGFR inhibitors: a rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC","volume":"46","author":"Liao","year":"2024","journal-title":"Head Neck"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e003402","DOI":"10.1136\/jitc-2021-003402","article-title":"PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment","volume":"10","author":"Collins","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3390\/ijms23073483","article-title":"High risk-human papillomavirus in HNSCC: present and future challenges for epigenetic therapies","volume":"23","author":"Ghiani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref24","first-page":"2163","article-title":"Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection","volume":"13","author":"Zhou","year":"2021","journal-title":"Am J Transl Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1013542","DOI":"10.3389\/fimmu.2022.1013542","article-title":"Human papillomavirus infection can alter the level of tumour stemness and T cell infiltration in patients with head and neck squamous cell carcinoma","volume":"13","author":"Meng","year":"2022","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e2216532120","DOI":"10.1073\/pnas.2216532120","article-title":"Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors","volume":"120","author":"Schrank","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/biom12101458","article-title":"FDCSP is an immune-associated prognostic biomarker in HPV-positive head and neck squamous carcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Biomolecules"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"10732748211011951","DOI":"10.1177\/10732748211011951","article-title":"DOCK8 Serves as a prognostic biomarker and is related to immune infiltration in patients with HPV positive head and neck squamous cell carcinoma","volume":"28","author":"Zhang","year":"2021","journal-title":"Cancer Control"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"997115","DOI":"10.3389\/fimmu.2022.997115","volume":"13","author":"Sarsembayeva","year":"2022","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-18-3301","article-title":"Cannabinoids promote progression of HPV-positive head and neck squamous cell carcinoma via p38 MAPK activation","volume":"26","author":"Liu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e34761","DOI":"10.1097\/MD.0000000000034761","article-title":"Involvement of KLRK1 in immune infiltration of head and neck squamous cell carcinoma correlates with favorable prognosis","volume":"102","author":"Tan","year":"2023","journal-title":"Medicine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"112823","DOI":"10.1016\/j.celrep.2023.112823","article-title":"SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck","volume":"42","author":"Nigam","year":"2023","journal-title":"Cell Rep"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"110854","DOI":"10.1016\/j.isci.2024.110854","article-title":"Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models","volume":"27","author":"Tsai","year":"2024","journal-title":"iScience"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"22354","DOI":"10.1002\/cam4.6715","article-title":"TTC7B is a new prognostic biomarker in head and neck squamous cell carcinoma linked to immune infiltration and ferroptosis","volume":"12","author":"He","year":"2023","journal-title":"Cancer Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3892\/ol.2021.12550","article-title":"PSMC2, ORC5 and KRTDAP are specific biomarkers for HPV\u2011negative head and neck squamous cell carcinoma","volume":"21","author":"Su","year":"2021","journal-title":"Oncol Lett"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"152802","DOI":"10.1016\/j.imbio.2024.152802","article-title":"PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K\/AKT\/mTOR pathway","volume":"229","author":"Wang","year":"2024","journal-title":"Immunobiology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/15384101.2021.2021722","article-title":"PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K\/Akt pathway","volume":"21","author":"Wang","year":"2022","journal-title":"Cell Cycle"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"607021","DOI":"10.3389\/fonc.2021.607021","article-title":"PSMC2 regulates cell cycle progression through the p21\/Cyclin D1 pathway and predicts a poor prognosis in human hepatocellular carcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12920-023-01696-4","article-title":"Lymph node metastasis related gene BICC1 promotes tumor progression by promoting EMT and immune infiltration in pancreatic cancer","volume":"16","author":"Meng","year":"2023","journal-title":"BMC Med Genomics"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1023292","DOI":"10.3389\/fonc.2023.1023292","article-title":"USP20 is a predictor of poor prognosis in colorectal cancer and associated with lymph node metastasis, immune infiltration and chemotherapy resistance","volume":"13","author":"Jin","year":"2023","journal-title":"Front Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/carcin\/bgn108","article-title":"CXCL12\/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1\/2\/AP-1 pathway","volume":"29","author":"Tan","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.radonc.2017.10.008","article-title":"SDF-1\/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy","volume":"126","author":"De-Colle","year":"2018","journal-title":"Radiother Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/odi.13694","article-title":"GPD1L is negatively associated with HIF1\u03b1 expression and predicts lymph node metastasis in oral and HPV-Oropharyngeal cancer","volume":"27","author":"Liu","year":"2021","journal-title":"Oral Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"9162249","DOI":"10.1155\/2023\/9162249","article-title":"Identification of GPD1L as a potential prognosis biomarker and associated with immune infiltrates in lung adenocarcinoma","volume":"2023","author":"Fan","year":"2023","journal-title":"Mediators Inflamm"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.reth.2021.02.006","article-title":"Immune evasion by cancer stem cells","volume":"17","author":"Tsuchiya","year":"2021","journal-title":"Regen Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"113628","DOI":"10.1016\/j.yexcr.2023.113628","article-title":"A novel metabolic-related gene signature for predicting clinical prognosis and immune microenvironment in head and neck squamous cell carcinoma","volume":"428","author":"Cao","year":"2023","journal-title":"Exp Cell Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12964-023-01043-1","article-title":"c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment","volume":"21","author":"Gao","year":"2023","journal-title":"Cell Commun Signal"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.csbj.2022.06.046","article-title":"Identifies microtubule-binding protein CSPP1 as a novel cancer biomarker associated with ferroptosis and tumor microenvironment","volume":"20","author":"Wang","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/j.csbj.2022.06.039","article-title":"Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers","volume":"20","author":"Wang","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"114504","DOI":"10.1016\/j.addr.2022.114504","article-title":"Cancer-associated fibroblasts: origin, function, imaging, and therapeutic targeting","volume":"189","author":"Rimal","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/odi.15130","article-title":"CAF-secreted COL5A2 activates the PI3K\/AKT pathway to mediate erlotinib resistance in head and neck squamous cell carcinoma","volume":"31","author":"Guo","year":"2025","journal-title":"Oral Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41698-023-00460-2","article-title":"Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGF\u03b1-EGFR paracrine signaling","volume":"7","author":"Su","year":"2023","journal-title":"npj Precis Oncol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1136\/ard.2008.098459","article-title":"The PI3K\/Akt\/mTOR pathway in innate immune cells: emerging therapeutic applications","volume":"67","author":"Weichhart","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref54","first-page":"178","article-title":"The Effects of PI3K\/Akt\/mTOR signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line","volume":"21","author":"Taghiloo","year":"2022","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/cancers13061233","article-title":"AKT3 is a novel regulator of cancer-associated fibroblasts in head and neck squamous cell carcinoma","volume":"13","author":"Takahashi","year":"2021","journal-title":"Cancers"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"8810804","DOI":"10.1155\/2024\/8810804","article-title":"FAP serves as a prognostic biomarker in head and neck squamous cell carcinoma","volume":"2024","author":"Liao","year":"2024","journal-title":"Anal Cell Pathol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.32604\/or.2024.046965","article-title":"Fibroblast activation protein (FAP) as a prognostic biomarker in multiple tumors and its therapeutic potential in head and neck squamous cell carcinoma","volume":"32","author":"Li","year":"2024","journal-title":"Oncol Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"668349","DOI":"10.3389\/fonc.2021.668349","article-title":"CAFs interacting with TAMs in tumor microenvironment to enhance tumorigenesis and immune evasion","volume":"11","author":"Gunaydin","year":"2021","journal-title":"Front Oncol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.trecan.2023.01.007","article-title":"From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts","volume":"9","author":"Arpinati","year":"2023","journal-title":"Trends Cancer"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/s41467-024-49282-1","article-title":"Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development","volume":"15","author":"Varveri","year":"2024","journal-title":"Nat Commun"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.3390\/cancers15174303","article-title":"ACLP activates cancer-associated fibroblasts and inhibits CD8+ T-cell infiltration in oral squamous cell carcinoma","volume":"15","author":"Sekiguchi","year":"2023","journal-title":"Cancers"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cytogfr.2013.07.003","article-title":"Vascular galectins: regulators of tumor progression and targets for cancer therapy","volume":"24","author":"Thijssen","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.3390\/cancers14225475","article-title":"Galectins are central mediators of immune escape in pancreatic ductal adenocarcinoma","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1535-6108(04)00024-8","article-title":"Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege","volume":"5","author":"Rubinstein","year":"2004","journal-title":"Cancer Cell"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/0008-5472.CAN-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","article-title":"Targeting tumor-associated macrophages for cancer treatment","volume":"12","author":"Li","year":"2022","journal-title":"Cell Biosci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2203073","DOI":"10.1080\/2162402X.2023.2203073","article-title":"Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome","volume":"12","author":"Zhang","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1186\/s12903-023-03421-0","article-title":"CERCAM is a prognostic biomarker associated with immune infiltration of macrophage M2 polarization in head and neck squamous carcinoma","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Oral Health"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-022-03357-4","article-title":"NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"ref71","first-page":"8279","article-title":"Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer","volume":"16","author":"Fang","year":"2024","journal-title":"Aging"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"21488","DOI":"10.1038\/s41598-023-48801-2","article-title":"RCN1 deficiency inhibits oral squamous cell carcinoma progression and THP-1 macrophage M2 polarization","volume":"13","author":"Liu","year":"2023","journal-title":"Sci Rep"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/hed.27734","article-title":"EGFR overexpression and macrophage infiltration correlate with poorer prognosis in HPV-negative oropharyngeal cancer via STAT6 signaling","volume":"46","author":"Lee","year":"2024","journal-title":"Head Neck"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1038\/s41467-024-51096-0","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"e157285","DOI":"10.1172\/jci.insight.157285","article-title":"Macrophage secretory IL-1\u03b2 promotes docetaxel resistance in head and neck squamous carcinoma via SOD2\/CAT-ICAM1 signaling","volume":"7","author":"Hsieh","year":"2022","journal-title":"JCI Insight"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.7150\/jca.98426","article-title":"Unlocking the secrets of extracellular vesicles: orchestrating tumor microenvironment dynamics in metastasis, drug resistance, and immune evasion","volume":"15","author":"Mir","year":"2024","journal-title":"J Cancer"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40364-023-00540-2","article-title":"Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology","volume":"11","author":"Asleh","year":"2023","journal-title":"Biomark Res"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41467-022-29469-0","article-title":"CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity","volume":"13","author":"Bernareggi","year":"2022","journal-title":"Nat Commun"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-021-02222-z","article-title":"M1-like tumor-associated macrophages cascade a mesenchymal\/stem-like phenotype of oral squamous cell carcinoma via the IL6\/Stat3\/THBS1 feedback loop","volume":"41","author":"You","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"110094","DOI":"10.1016\/j.intimp.2023.110094","article-title":"Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway","volume":"118","author":"Li","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"106524","DOI":"10.1016\/j.oraloncology.2023.106524","article-title":"Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1\/JAK1\/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer","volume":"145","author":"Han","year":"2023","journal-title":"Oral Oncol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13578-019-0325-8","article-title":"Colon cancer cells secrete exosomes to promote self-proliferation by shortening mitosis duration and activation of STAT3 in a hypoxic environment","volume":"9","author":"Ren","year":"2019","journal-title":"Cell Biosci"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41598-022-05161-7","article-title":"Hypoxia-induced HIF1\u03b1 activation regulates small extracellular vesicle release in human embryonic kidney cells","volume":"12","author":"Mu\u00f1iz-Garc\u00eda","year":"2022","journal-title":"Sci Rep"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"e12310","DOI":"10.1002\/jev2.12310","article-title":"Hypoxia promotes EV secretion by impairing lysosomal homeostasis in HNSCC through negative regulation of ATP6V1A by HIF-1\u03b1","volume":"12","author":"Wang","year":"2023","journal-title":"J Extracell Vesicles"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12964-023-01450-4","article-title":"Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRP\u03b1 axis","volume":"22","author":"Chen","year":"2024","journal-title":"Cell Commun Signal"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00018-024-05210-6","article-title":"Tumor-associated macrophage-derived exosomal miR21-5p promotes tumor angiogenesis by regulating YAP1\/HIF-1\u03b1 axis in head and neck squamous cell carcinoma","volume":"81","author":"Yan","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"12904","DOI":"10.3390\/ijms241612904","volume":"24","author":"Wu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00432-024-05731-4","article-title":"Construction and validation of a folate metabolism-related gene signature for predicting prognosis in HNSCC","volume":"150","author":"Wang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"C362","DOI":"10.1152\/ajpcell.00061.2023","article-title":"TLR9 activation induces immunosuppression and tumorigenesis via PARP1\/PD-L1 signaling pathway in oral squamous cell carcinoma","volume":"326","author":"Ma","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1038\/s41598-020-60707-x","article-title":"Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma","volume":"10","author":"Jung","year":"2020","journal-title":"Sci Rep"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"e002699","DOI":"10.1136\/jitc-2021-002699","article-title":"PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy","volume":"9","author":"Xu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","article-title":"CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis","volume":"4","author":"Lerner","year":"2023","journal-title":"Nat Cancer"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2326-6066.CIR-22-0815","article-title":"High expression of MHC class I overcomes cancer immunotherapy resistance due to IFN\u03b3 signaling pathway defects","volume":"11","author":"Kawase","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2326-6066.CIR-23-0622","article-title":"Hypoxia-induced long noncoding RNA HIF1A-AS2 regulates stability of MHC class I protein in head and neck cancer","volume":"12","author":"Liao","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3389\/fonc.2020.00615","article-title":"Long non-coding RNA LINC02195 as a regulator of MHC I molecules and favorable prognostic marker for head and neck squamous cell carcinoma","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/jop.13485","article-title":"Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro","volume":"52","author":"Wang","year":"2023","journal-title":"J Oral Pathol Med"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41368-023-00221-8","article-title":"Down-regulation of DNA key protein-FEN1 inhibits OSCC growth by affecting immunosuppressive phenotypes via IFN-\u03b3\/JAK\/STAT-1","volume":"15","author":"Wang","year":"2023","journal-title":"Int J Oral Sci"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"2021619","DOI":"10.1080\/2162402X.2021.2021619","article-title":"Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma","volume":"11","author":"Kono","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"106309","DOI":"10.1016\/j.oraloncology.2023.106309","article-title":"Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer","volume":"138","author":"Robbins","year":"2023","journal-title":"Oral Oncol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cas.15619","article-title":"Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation","volume":"114","author":"Komatsuda","year":"2023","journal-title":"Cancer Sci"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"13784","DOI":"10.1080\/21655979.2022.2084254","article-title":"CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma","volume":"13","author":"Wei","year":"2022","journal-title":"Bioengineered"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"e005088","DOI":"10.1136\/jitc-2022-005088","article-title":"SP140 inhibits STAT1 signaling, induces IFN-\u03b3 in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response","volume":"10","author":"Tanagala","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.174.8.4880","article-title":"STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion","volume":"174","author":"Kusmartsev","year":"2005","journal-title":"J Immunol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41590-022-01398-6","article-title":"YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells","volume":"24","author":"Ma","year":"2023","journal-title":"Nat Immunol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"3946320241227312","DOI":"10.1177\/03946320241227312","article-title":"CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma","volume":"38","author":"Lin","year":"2024","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00262-024-03789-0","article-title":"Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy","volume":"73","author":"Yan","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-022-03310-5","article-title":"Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1063711","DOI":"10.3389\/fimmu.2022.1063711","article-title":"Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","article-title":"B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma","volume":"12","author":"Ruffin","year":"2021","journal-title":"Nat Commun"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12957-022-02703-1","article-title":"Prognostic biomarker IL17A correlated with immune infiltrates in head and neck cancer","volume":"20","author":"Yu","year":"2022","journal-title":"World J Surg Oncol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1080\/07853890.2022.2095664","article-title":"The role of toll-like receptors (TLRs) in pan-cancer","volume":"54","author":"Huang","year":"2022","journal-title":"Ann Med"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/164_2021_541","article-title":"TLR10 and its role in immunity","volume":"276","author":"Fore","year":"2021","journal-title":"Toll-like receptors in health and disease"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000524461","article-title":"Regulation of TLR10 expression and its role in chemotaxis of human neutrophils","volume":"14","author":"Balachandran","year":"2022","journal-title":"J Innate Immun"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13205-022-03420-y","article-title":"Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC","volume":"13","author":"Khan","year":"2023","journal-title":"3 Biotech"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: tthe final results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","article-title":"A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma","volume":"13","author":"Ju","year":"2022","journal-title":"Nat Commun"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-17-0357","article-title":"Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals","volume":"24","author":"Shayan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"e007364","DOI":"10.1136\/jitc-2023-007364","article-title":"Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors","volume":"12","author":"Khushalani","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/cac2.12273","article-title":"Aberrant translation regulated by METTL1\/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41416-020-01074-2","article-title":"Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck","volume":"123","author":"Kim","year":"2020","journal-title":"Br J Cancer"},{"key":"ref132","first-page":"100725","article-title":"Eftilagimod alpha (a Soluble LAG-3 Protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti-programmed cell death protein 1\/programmed death-ligand 1-based therapy: final results from a phase 2 study","volume":"5","author":"Krebs","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4143\/crt.2023.433","article-title":"A phase II trial of nintedanib in patients with metastatic or recurrent head and neck squamous cell carcinoma: in-depth analysis of nintedanib arm from the KCSG HN 15-16 TRIUMPH trial","volume":"56","author":"Kim","year":"2024","journal-title":"Cancer Res Treat"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-6\/OncolRes-33-06-62207\/OncolRes-33-62207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T01:35:17Z","timestamp":1763343317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n6\/61349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":134,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.062207","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"2024-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}